To examine the lysis of virus-infected cells in vivo, uninfected and lymphocytic choriomeningitis virus (LCMV)-infected L-929 cells were labeled in vitro with [1251]-iododeoxyuridine and implanted intravenously into mice. Natural cytotoxicity against both uninfected and virus-infected cells was demonstrated in normal uninfected mice, but LCMV-infected cells were cleared from the lungs and whole bodies more rapidly than uninfected cells. Treatment of L-929 cells with defective interfering LCMV inhibited standard virus synthesis and protected the target cells from enhanced in vivo rejection. The in vivo rejection was apparently mediated by a cellular constituent of the host immune response and not simply a result of virusinduced cytopathic effects on the target cell, as hydrocortisone acetate and cyclophosphamide each reduced rejection of both target cell types and eliminated the enhanced rejection of LCMV-infected cells. The enhanced rejection of LCMV-infected cells was not restricted by histocompatibility antigens, indicating that classic T-cell recognition was not involved in the lysis, and since the enhanced rejection of LCMV-infected cells was mediated by mice treated with cobra venom factor, complement was also not involved in the lysis. Although moderate levels of interferon (102 U/ml) were present in the sera and although there was a modest activation of natural killer (NK) cells in the lungs of LCMV-infected cell recipients but not uninfected cell recipients, the enhanced rejection of virus-infected cells did not appear to be NK cell mediated. Normal mice and mice depleted of NK cell activity by in vivo treatment with antibody to asialo ganglio-ntetraosylceramide (AGM1) rejected uninfected and LCMV-infected L-929 cells similarly. This antibody markedly inhibited the rejection of NK-sensitive YAC-1 cells. In addition to the natural cytotoxicity directed against virus-infected cells, a second nonspecific rejection mechanism appeared in response to treatment protocols which induced interferon. Polyinosinic-polycytidylic acid and infection with LCMV augmented in vivo rejection of both uninfected and LCMV-infected L-929 cells but eliminated the differential rejection of the virus-infected cells. Infection with LCMV also augmented the in vivo rejection of the NK-sensitive target cell, YAC-1. In vivo treatments with anti-AGM1 sera only moderately inhibited the elevated rejection of uninfected and LCMV-infected L-929 cells, indicating that the enhanced rejection of these target cells was predominantly mediated by a mechanism other than that mediated by NK cells. In contrast, rejection of YAC-1 cells in both uninfected and LCMV-infected mice was dramatically reduced by treatment with anti-AGM1 serum. These results demonstrate two in vivo rejection mechanisms (other than NK cells) which may contribute to the control of virus infection: (i) a selective natural cytotoxicity directed against virus-infected cells and (ii) a nonselective rejection mechanism activated during virus infection. These may be two manifestations of the same mechanism, but both appear to be distinct from those mediated by AGM1-positive NK cells.
Natural immunity may play an important role in the initial defense against virus infection. This may take the form of direct inactivation of viruses by serum components, inhibition of virus synthesis by interferon (IFN), or perhaps direct lysis of virus-infected cells. The latter point, i.e., direct or preferential lysis of virus-infected cells in vivo, has never been demonstrated. It has been hypothesized to occur because virus-infected cells are frequently more susceptible to lysis by nonimmune leukocytes in vitro. The cell type most commonly associated with such lysis is the natural killer (NK) cell, although other cell types could also be involved (for a review, see reference 34).
Virus infections induce IFN which in turn activates NK cells to become more cytolytic (28, 33) . The sensitivity of virus-infected target cells to lysis mediated by NK cells has been examined in several different in vitro systems (3, 28, in vivo, we examined the rejection of [125I]iododeoxyuridine (IUDR)-labeled uninfected and virus-infected cells from mice. The data presented in this paper demonstrate that (i) lymphocytic choriomeningitis virus (LCMV)-infected cells are cleared more rapidly than uninfected cells in vivo, even though they are not preferentially lysed by nonimmune leukocytes in vitro, (ii) the rejection is mediated by a host response sensitive to treatments with immunopharmacological agents but distinct from NK cells, and (iii) a nonspecific rejection mechanism, in addition to that mediated by NK cells, is activated during virus infection.
MATERIALS AND METHODS
Mice. C3H/St mice were purchased from West Seneca Laboratories, West Seneca, N.Y. They were maintained in our facilities for at least 3 weeks before use. C57BL/6 mice were originally purchased from Jackson Laboratories, Bar Harbor, Maine, and then bred in our own facilities. Unless stated otherwise, female mice at 10 to 16 weeks of age were used.
Virus. The Armstrong strain of LCMV was propagated in L-929 cells for use in these experiments. Standard (S) LCMV was harvested from acutely infected cells. Defective interfering (DI) LCMV was harvested from a persistently infected L-929 cell line and concentrated 100-fold for use in these experiments (37) . The Indiana strain of vesicular stomatitis virus was used in the IFN assays.
Cells. The YAC-1 cell line is a Moloney leukemia virusinduced T-cell lymphoma of mouse strain A/Sn origin; it is extremely sensitive to lysis by endogenous (control) NK cells (16) . The YAC-1 cell line was maintained in RPMI 1640 medium (GIBCO Laboratories, Grand Island, N.Y.) supplemented with antibiotics (penicillin and streptomycin), glutamine, and 10% heat-inactivated fetal bovine serum (M. A. Bioproducts, Walkerville, Md.). L-929 is a continuous H-2k fibroblast line relatively insensitive to endogenous NK cellmediated lysis but is lysed by NK cells activated in vivo during virus infection (33) . MC57G is a continuous H-2b fibroblast cell line. L-929 and MC57G cells were grown in Eagle minimal essential medium (MEM; GIBCO) supplemented with antibiotics, glutamine, and 10% fetal bovine serum. Three days before in vivo rejection experiments, the fibroblast lines were seeded at 1.5 x 106 cells per 75-cm2 flask and either left uninfected or infected with 0.1 PFU of S LCMV per cell (multiplicity of infection, 0.1). Uninfected YAC-1 target cells were seeded at 0.2 x 106 cells per ml 1 day before the experiment.
In vivo rejection assay. Target cells were labeled in vitro in a 5% CO2 incubator at 37°C. Label In vivo treatments. Mice were treated with hydrocortisone acetate in suspension (Hydrocortone; Merck Sharp & Dohme, West Point, Pa.) by intraperitoneal (i.p.) injection of 2.5 mg at 3 days and 3.75 mg at 1 day before use in in vivo rejection experiments. Cyclophosphamide (Sigma Chemical Co., St. Louis, Mo.) was dissolved in 0.85% NaCl immediately before use, and mice were given (i.p.) 300 mg/kg of body weight 4 days before the experiments. Cobra venom factor (CVF; Cordis Laboratories, Miami, Fla.) was reconstituted in ice-cold water and stored at -70°C. CVF was diluted 1:2 in cold (4°C) phosphate-buffered saline immediately before use, and 15 U was administered i.p. on 3 and 1 days before the experiments (5). Mice were infected i.p. with 104 PFU of LCMV at various times before use. Polyinosinicpolycytidylic acid [poly(I):(C); Sigma] was made up at 0.4 mg/ml in 0.85% NaCl, and mice received (i.v.) a dose of S mg of poly(I):(C) per kg of body weight 1 day before use. Antiserum to anti-AGM1 (10) was diluted 1:5 in RPMI 1640 medium immediately before use, and the equivalent of 20 ,ul of undiluted serum was administered i.v. 2 days before the experiment.
In vitro cytotoxicity assays. Spleen effector cells were isolated as previously described (2, 33) . Spleen cells were teased apart in RPMI 1640 medium and filtered through a nylon mesh. Cells were centrifuged at 400 x g for 5 min, resuspended in 0.83% NH4Cl to lyse the erythrocytes, pelleted, and washed in RPMI 1640 medium. A modification of the protocol described by Puccetti et al. (24) was used to isolate lung effector cells with minimal contamination by peripheral blood cells. Mice were anesthesized, the interior vena cava was severed, and 10 ml of cold RPMI 1640 medium, containing 10 U of heparin per ml, was flushed through the lungs by injection into the right ventricle. The lungs were then removed, washed in RPMI 1640 medium, and minced into small pieces. The pieces were incubated at 4°C in medium for 1 h, flushed up and down in a syringe, filtered through fine gauze, and finally centrifuged at 400 x g for 5 min.
Microcytotoxicity assays were performed in vitro as previously described (2, 33) . Briefly, target cells (106) were labeled with sodium chromate (51Cr; New England Nuclear) for 1 h (37°C) at a concentration of 100 ,uCi per pellet of cells. After labeling, cells were centrifuged and washed, and 104 target cells were used per assay. Medium was added to cells used for spontaneous lysis determinations, and 1% Nonidet P-40 was added shortly before harvest to a set of target cell wells to determine 100% lysis. Microtiter plates were incubated from 4 to 18 h. Before harvest, plates were centrifuged at 200 x g for 5 min, and 0.1 ml was collected for radioactivity counting. Quadruplicate samples counted had standard deviations of less than 5% of the mean. Data are expressed as percent specific 51Cr release (lysis) = 100 x [(cpm of test samples -cpm of medium controls)/(cpm of Nonidet P-40 controls -cpm of medium controls)], where cpm is the counts per minute. Spontaneous release never exceeded 10% in short (4 h) assays or 35% in long (18 h) assays.
IFN assays. Blood was collected from the retroorbital sinus of anaesthetized mice. After clotting, the serum was obtained by centrifugation. Lungs were harvested from individual animals, homogenized in 2.5 ml of 10% fetal bovine serum-MEM, and centrifuged at 400 x g to remove cellular debris. Samples for IFN assays were serially diluted twofold and used in a microtiter plate assay with L-929 cells as described elsewhere (4) . After an 18-to 24-h incubation with the IFN test samples, L-929 cells were challenged with vesicular stomatitis virus and scored 2 and 3 days later for reduction in cytopathic effects.
Immunofluorescence assay. Cell surface antigens were stained directly with monospecific anti-LCMV guinea pig immunoglobulin G conjugated to fluorescein isothiocyanate as previously described (37) . The (Fig. la) . The cells were primarily localized in the lungs, from which over 80% of the counts were recovered (Fig. lb) . Although there was no difference in the initial implantation of uninfected and virus-infected cells, the LCMV-infected cells were cleared more rapidly than the uninfected cells. By 18 h postinjection, only 11% of the LCMV-infected cell counts remained in the whole bodies of injected mice, whereas 21% of the cell counts remained in those mice injected with uninfected cells.
Rejection of 125I-labeled target cells from the whole body correlated directly with the clearance from the lungs; the difference between the percent counts remaining in whole bodies was comparable to the difference between the percent counts remaining in the lungs ( Fig. 1 and Table 1 ). Use of the lung, rather than whole body, to measure counts eliminated the problem of residual whole body counts due to iodine localization in the thyroid or bladder. Livers and spleens never retained significant counts ( Table 1 ). The implantation into and rejection from the lungs was therefore examined more closely.
Cell implantation and retention in the lungs was dependent on the viability of target cells. Dead cells were rapidly cleared from the lungs; by 4 h postinjection, when >50% of the counts contained in live L-929 cells were recovered in the lungs, <1% of the counts contained in the froz:.. .nd thawed cells were recovered (data not shown). The terminology percent counts recovered and percent cells recovered are used interchangeably in the remainder of this paper.
Defective interfering virus-induced resistance. DI LCMV specifically blocks S LCMV synthesis and inhibits production of LCMV antigens on the membranes of infected cells (35, 37) . To examine the effect of DI virus on the in vivo rejection of S virus-infected cells, L-929 cells were exposed to DI LCMV before infection with S LCMV. In addition to inhibiting the expression of LCMV surface antigens, this treatment induced resistance to the in vivo rejection directed against virus-infected cells (Table 2) . At a time when only 20% of the 1251 counts contained in S LCMV-infected cells were recovered in the lungs, 40% of the 125I counts contained in either uninfected cells or cells infected first with DI virus and then challenged with S virus could be recovered. Differential rejection in vivo of LCMV-infected cells, therefore, required S LCMV synthesis and was not due to contamination of the S LCMV stock with another microorganism.
In vivo rejection after depletion of cellular constituents. The LCMV infection of L-929 cells is relatively noncytopathic in vitro, but it was nevertheless important to determine whether the differential rejection in vivo was due simply to a virusinduced cytopathology or to a host response function. Treatments with either hydrocortisone acetate or cyclophosphamide inhibit several cellular functions of the immune system, including NK cell-mediated lysis (14, 21, 25, 26) . Treatments with hydrocortisone acetate that reduced spleen cell yields by 70% reduced in vivo rejection of both uninfected and LCMV-infected cells (Fig. 2a) . In addition, the statistically significant differential rejection between uninfected and virus-infected cells was no longer apparent. Virtually identical results were obtained when animals were treated with cyclophosphamide under conditions that reduced spleen cell yields by greater than 90% (Fig. 2b) . Since the recoveries in the drug-treated recipients were the same for both the uninfected and LCMV-infected cells, it can be concluded that the differential rejection of virus-infected cells was due to a drug-sensitive constituent of the host response and was not simply a result of virusinduced lysis of infected cells. In contrast to the results described above, treatment protocols that depleted complement activity did not alter differential rejection of virus-infected cells. Treatments with CVF that reduced serum C3 levels by >90%, as measured by the ability to form erythrocyte-antibody complement complexes, slightly increased in vivo rejection of both uninfected and LCMV-infected L-929 cells but had no effect on the differential rejection (Fig. 3) .
Histocompatibility requirements. To determine whether in vivo rejection was restricted to histocompatible target cells infected with LCMV, the rejection of H-2k cells (L-929) and H-2b cells (MC57G) was examined in an H-2k mouse strain, C3H/St, and an H-2b mouse strain, C57BL/6. Both the histoincompatible LCMV-infected cells and the histocompatible LCMV-infected cells were rejected more rapidly than their uninfected counterparts ( Table 3 Table 4) . The elevated NK cell activity peaks 2 to 4 days postinfection with LCMV and then subsides. Augmented NK cell-mediated lysis could be demonstrated with cells isolated from the lungs of mice at the time of peak spleen NK cell activity. In contrast to the NK cells isolated from the lungs of uninfected mice, which mediated only 5% lysis, NK cells prepared from the lungs of mice on day 3 postinfection with LCMV mediated 17% lysis of YAC-1 target cells in a 51Cr release assay. Cytotoxic T cells specific for histocompatible cells expressing LCMV antigens develop later and peak at 7 to 10 days postinfection (Fig. 4a) (33, 39) . The effect of these mechanisms on the rejection of uninfected and LCMVinfected cells in vivo was examined. Both uninfected and LCMV-infected mice had greater than 95% of the counts located in the lungs immediately after injection. The clearance of uninfected and LCMV-infected L-929 cells was, however, markedly augmented on day 3 postinfection, and the differential rejection of virus-infected cells was no longer apparent (Fig. 4b) . The augmented rejection on day 3 postinfection was apparently mediated by a cellular constituent of the host response, as treatments with cyclophosphamide before LCMV infection dramatically inhibited the rejection in infected mice (data not shown). On day 9 postinfection, a time when in vitro assays demonstrated that NK cell-mediated activity was declining but cytotoxic T-cell activity was high, the LCMV-infected cells were again rejected more rapidly than uninfected cells (Fig. 4c) .
Since poly(I):(C) induces IFN and activates NK cells in vivo (6, 26) uninfected and LCMV-infected cells, mice were treated with anti-AGM1 serum in vivo under conditions which selectively eliminated endogenous and activated NK cells for several days (Table 5 ) (4, 10). Injection of 20 ,ul of anti-AGM1 at 2 days before the experiment completely eliminated spleen NK cell activity recovered from both uninfected and LCMVinfected cell re_ipients but did not inhibit IFN induction (Table 5) . Anti-AGM1 treatments did not alter implantation of the NK-sensitive target cell, YAC-1, in the lung but significantly inhibited the in vivo rejection of this target cell. Immediately after injection, 91% of the YAC-1 cell counts were recovered in the lungs of normal animals and 88% were recovered in the lungs of anti-AGM1-treated animals. At 2 h postinjection, a time at which <2% of the injected YAC-1 cell counts were recovered in the lungs of normal animals, over 30% of the YAC-1 cell counts were recovered in the lungs of anti-AGM1-treated mice (Fig. 7) . In contrast, treatments with anti-AGM1 had relatively little effect on the in vivo rejection of either uninfected or LCMV-infected L-929 cells, and the differential rejection of LCMV-infected cells was still observed (Fig. 7) .
Effect of NK cell depletion on augmented rejection. We next examined the effect of anti-AGM1 treatment on the augmented rejection observed during virus infection, originally shown in Fig. 4b . Mice infected with LCMV 3 days before the experiment and then treated with anti-AGM1 had high levels of IFN but were drastically depleted of spleen NK cell activity (Table 5 , experiment 2). The in vivo rejection of YAC-1, uninfected L-929, and LCMV-infected L-929 cells was augmented in virus-infected mice, but only the elevated rejection of YAC-1 target cells was dramatically reduced by treatment with anti-AGM1 (Fig. 8) . Treatment of LCMVinfected mice with anti-AGM1 inhibited in vivo rejection such that the YAC-1 cell counts recovered in the lungs of activated, anti-AGM1-treated mice was almost threefold higher than those recovered in control uninfected mice (Fig.  8) . Although it is clear that NK cells isolated from LCMVinfected mice lyse uninfected and LCMV-infected L-929 cells in vitro (Table 4) 41,000 1.7 a Target L-929 cells were prepared as described in the text. Sera and spleens were harvested from groups of four to six mice 4 h after injection of target cells. augmented in vivo rejection against these target cells during virus infection was inhibited by treatment with anti-AGM1; the cell counts recovered with either uninfected or LCMVinfected cells were still significantly lower in LCMV-infected anti-AGM1-treated mice than the counts recovered in control uninfected mice (Fig. 8) .
DISCUSSION We believe this to be the first documentation that virusinfected target cells are preferentially and rapidly lysed within nonimmune mice. By examining the clearance of
[1251I]IUDR-labeled cells in vivo, it was demonstrated that uninfected mice rejected LCMV-infected L-929 cells more rapidly than uninfected L-929 cells (Fig. 1) . Pretreatments with DI LCMV reduced the synthesis of S LCMV (Table 2 ) and the rate of in vivo rejection, indicating that the rejection required LCMV synthesis and was not a consequence of a contaminant in the LCMV stock. The clearance of 125i counts was mediated by the host and was not simply a result of virus-induced cytopathic effects in the cells; treatments with hydrocortisone acetate and cyclophosphamide, which inhibited cellular constituents of the immune system, ablated the differential rejection of LCMV-infected cells (Fig. 2) . Although NK cells were among the cellular constituents inhibited by the drug regimens used (14, 25) , NK cells did not appear to mediate the differential rejection of LCMVinfected cells; treatments with anti-AGM1 serum in vivo depleted NK cell activity and significantly depressed the in vivo rejection of the NK-sensitive target cell, YAC-1, but had little effect on the rejection of either uninfected or LCMV-infected L-929 cells (Fig. 7) .
In addition to the natural cytotoxicity directed against virus-infected target cells, a nonspecific rejection mechanism activated on day 3 postinfection with LCMV could also be demonstrated (Fig. 4) . NK cells activated at this time ( whether this nonspecific rejection mechanism observed on day 3 postinfection with LCMV is mediated by the same mechanism as the differential rejection of virus-infected cells in uninfected mice (Fig. 7) . (22) . Selective depletion of NK cells in vivo by treatment with anti-AGM1 serum has been shown to result in increased tumor cell growth (10, 15) and spreading during experimental metastasis (9) . Specific in vivo reduction of NK cell activity in control uninfected mice also results in a reduction in the clearance of 125I-labeled YAC-1 target cells extremely sensitive to in vitro lysis mediated by endogenous NK cells (9, 23) . We extended the previous work by examining the in vivo rejection of 1251_ labeled YAC-1 cells and show that not only is the rejection in control uninfected mice mediated by NK cells (Fig. 7) but also that on day 3 postinfection with LCMV there is an elevated rejection of YAC-1 target cells mediated by NK cells (Fig. 8) .
Implanted tumor cells are not always sensitive to an AGM1-dependent mechanism. When Kawase and co-workers (15) (Fig.  7) . In addition, a rejection mechanism predominantly independent of AGM1-positive cells is highly active on day 3 postinfection with LCMV (Fig. 8) .
Complement has also been implicated in the defense against virus infection. Cells infected with LCMV can activate complement (37) , and complement-depleted animals are more susceptible to Sindbis virus infection (13) . Complement does not, however, appear to play an important role in the in vivo rejection of LCMV-infected L-929 cells since treatment with CVF depleted serum complement levels but did not eliminate the enhanced rejection of these target cells (Fig. 3) .
These results apparently indicate that at least two rejection mechanisms are present and activated in the lung during LCMV infection. The first is NK cell mediated, presumably activated during LCMV infection by viral IFN and directed against YAC-1 cells (Fig. 7 and 8) . The second rejection mechanism is directed against L-929 cells and is not sensitive to anti-AGM1 serum ( Fig. 7 and 8 ). Since leukocyte prepara-VOL. 50, 1984 on July 6, 2017 by guest http://jvi.asm.org/ Downloaded from tions from lungs contain macrophages, NK cells, and a population of a natural cytotoxic (NC) cells clearly distinct from NK cells (24, 29; unpublished data), these populations must be considered. Both macrophages and NC cells differ from NK cells in their expression of AGM1 antigen, target cell range, and presence in older animals after NK cell activity has declined (18, 30, 31) . Although both of these populations have been reported to be relatively resistant to the cyclophosphamide treatments used here, a cyclophosphamide-sensitive cell may be required to activate either macrophages or NC cells upon exposure to LCMV-infected target cells. Experiments to delineate the cell mediating the lysis are hampered, at this time, by the lack of suitable reagents to specifically eliminate either macrophages or NC cells in vivo. Recently, it has been demonstrated that NC cells could be activated in vitro by interleukins other than IFN (18, 19) . Since such interleukins may be generated during LCMV infection, rejection mechanisms in addition to those mediated by NK cells could be activated during viral infections.
Several cellular effector mechanisms, in addition to that mediated by NK cells, may play a role in natural cytotoxicity against virus infections. An effector cell mediating preferential lysis in vitro of herpes simplex virus type 1 (HSV-1)-infected fibroblasts has recently been isolated from human peripheral blood (8, 20) . This population of cells, NK (HSV-1) cells, is clearly different from the classic NK cell in physical properties and antigen expression (7 
